Randomized, controlled trial of therapy interruption in chronic HIV-1 infection - Wikidata - awgldk - TriplyDB

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

http://www.wikidata.org/entity/Q24809608

about

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.Modelling imperfect adherence to HIV induction therapy Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV On the role of resonance in drug failure under HIV treatment interruption.Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resum Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.A cure for AIDS: a matter of timing?Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study.Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.Two-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults

P2860

Q21559730-A2350B06-90C1-4DAB-B548-3B549BEBE884 Q24245541-16AFB013-7C6C-46F7-A9AB-92DDD2555994 Q24245709-4735ECD4-3FBF-40CB-9132-53CA4C23FBEF Q28478848-003F61EE-4361-4C9C-97EF-840C8BDE5297 Q28537694-33920B12-4265-4EC1-B590-D4C6E0DD2459 Q33313949-AB09EF55-EA43-43EA-8FA4-B9096B668C6C Q33523201-37658E51-10B4-4C8F-B150-F55BD96919C4 Q33676532-E48F855A-F700-4021-BE3F-E8FC3D37783E Q33786318-6E2CAD51-A2BE-480A-88AC-2B7CBC228F35 Q33925025-9B801FDD-5A65-4296-8922-893E744DB14F Q33982102-F183BE45-1841-488A-8305-A0266BA76C22 Q34716901-48AF5D5F-F1CB-40C9-85DC-DBD3AAD37440 Q35115062-35A2E8D3-8FFD-488A-9E12-1C14BFC27BAD Q35833324-8B850F60-8E2F-4479-9967-432354305D7B Q35862206-5A1FBB5A-F2B4-44D2-95C1-B41A23EF73F4 Q36408455-CE219BF5-9642-40FB-8CD1-54C8341CAA3B Q36495526-513B296B-398C-4BE9-9803-1FC7C68FCE02 Q36544183-BB7359C6-1F49-4B90-9CD6-11BEF6704418 Q36654098-F6E330C6-E4B3-4920-8CCB-8EBE045F576C Q37033475-B3CF6BAE-F3BB-4E83-B658-BAE0B4153869 Q37304799-4B669787-C1A9-4096-A59E-906FD87B53A8 Q37304813-E4350937-ECC0-486A-83EE-D2E1E9339488 Q37349847-B9BDD91D-FF9D-4EBD-B94E-83055811F5BB Q38165451-07F3458E-5A49-44D6-BB7F-7C77DF638ED0 Q38777005-88A824E8-694C-44F8-9C79-498DFEA4BC54 Q40603410-48261811-6187-49E7-AC3C-9079C5769B0A Q41482141-9DAA971D-B2D2-46AD-9EBB-FE98B412DEF7 Q42360738-C317E9CC-AAD1-4F72-9844-FA008EDC5268 Q58827996-29D1E9D6-B1C1-469A-8A6F-6D950201CCCB

P2860

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

http://www.wikidata.org/entity/Q24809608

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@ast

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@en

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@nl

type

label

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@ast

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@en

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@nl

prefLabel

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@ast

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@en

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@nl

P1433

Q24809608-BB1A9182-3619-48C3-9D1F-595441DCCC50

P1476

Q24809608-2F99A618-C3BF-414C-94C7-9C470BBEBF01

P2093

Q24809608-0B80D285-407C-46D0-966F-5690F01A5AFE

Q24809608-179D5846-5870-48BB-9CF6-5D2D99830B6B

Q24809608-197DC7DB-9169-4782-A30A-2F274702357C

Q24809608-4AA26C0E-6AEC-4299-A773-4A44BA2E2090

Q24809608-668E8AC7-800C-40A7-A3E5-50E8CAF94741

Q24809608-86721395-EE69-4961-A3F1-CA3B866C455D

Q24809608-C633E9F6-8340-4BAC-9859-47719B4CF717

Q24809608-D2AE309A-2BCA-47F6-AB89-32990C2F0E6A

Q24809608-DD85E5B9-3146-4AAD-9F7B-9577863FDF6E

Q24809608-E58840D5-A9FD-4326-802E-D5B1AC1602EE

P2860

Q24809608-02EE8EF6-5FF7-4581-9A42-48502E3DE2AA

Q24809608-099AEFB8-EC8F-4826-B04C-C07EFD762C41

Q24809608-0DDA7D77-65F1-4D7F-86C4-AD5F469B5C7A

Q24809608-0F72D01D-60EE-4DEE-B761-F21214291787

Q24809608-16475282-9835-428B-8EF1-B45F979B2197

Q24809608-2967758F-4793-4B03-BB82-DAC73E25CA1C

Q24809608-2AE7C18A-F43B-4743-9FD6-6DCE66D47AD7

Q24809608-59467FC4-AE9F-4394-A999-C678AED5115C

Q24809608-5A4E0A27-A3B7-4093-9865-E1A15095AF2B

Q24809608-5D96FF7B-7C8B-4983-9CBA-E9BBCD5589F4

P304

Q24809608-54E32738-606A-4F0D-A50E-F7E9B59A9FAA

P31

Q24809608-C376F079-E4E4-41F9-B90A-A008DB3B03D7

P356

Q24809608-74426FD6-548D-454C-924A-A075CEEFAA46

P407

Q24809608-DCED273F-CAF3-4442-BC6A-8E0DCAAB3F5A

P433

Q24809608-4509C510-8BE8-41C1-8F2D-866FCCCA1D9E

P478

Q24809608-72878C4A-F8F5-49D0-8484-B8B1D012C575

P50

Q24809608-5E35A75F-5E25-4423-938C-A17335F32793

Q24809608-D92F53A9-A3D3-4AA4-923B-5DE31705776C

P577

Q24809608-8EA01426-1F41-4BAE-83DF-1B4C1184AA50

P5875

Q24809608-BB8AF328-2889-46EF-B3CC-D8761FE2A529

P698

Q24809608-440F825E-9756-4253-BB87-6AE26B40C14D

P932

Q24809608-9929A884-64DB-4159-A159-7FA76367964C

P356

JOURNAL.PMED.0010064

P1433

P1476

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

@en

P2093

Agnieszka Mackiewicz

http://www.w3.org/2001/XMLSchema#string

Andrea Foulkes

http://www.w3.org/2001/XMLSchema#string

Brian Thiel

http://www.w3.org/2001/XMLSchema#string

Cele Gallo

http://www.w3.org/2001/XMLSchema#string

Emmanouil Papasavvas

http://www.w3.org/2001/XMLSchema#string

Jane Shull

http://www.w3.org/2001/XMLSchema#string

Jay R Kostman

http://www.w3.org/2001/XMLSchema#string

Karam Mounzer

http://www.w3.org/2001/XMLSchema#string

Livio Azzoni

http://www.w3.org/2001/XMLSchema#string

Luis J Montaner

http://www.w3.org/2001/XMLSchema#string

P2860

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Structured treatment interruptions to control HIV-1 and limit drug exposure.

Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals

Structured treatment interruptions for the management of HIV infection.

Structured Treatment Interruption: Approaches and Risks.

STI and beyond: the prospects of boosting anti-HIV immune responses.

Accuracy of the TRUGENE HIV-1 genotyping kit.

P304

e64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.0010064

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Maxwell Pistilli

Robert M. Grant

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8101456

http://www.w3.org/2001/XMLSchema#string

P698

15630469

http://www.w3.org/2001/XMLSchema#string

P932

539050

http://www.w3.org/2001/XMLSchema#string